In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until eventually condition progression or perhaps the individuals are not able to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells per replicate have been https://abbv-744brd4inhibitioninc81245.spintheblog.com/32331787/5-easy-facts-about-abbv-744-combination-therapy-with-chemotherapy-described